Introduction
Transcatheter valve therapies initially emerged as an alternative to surgery for patients with heart valve disease and unmet treatment needs. Being rapidly adopted, its use has been greatly expanded and, nowadays, transcatheter aortic valve implantation (TAVI) and percutaneous mitral valve repair have become routine therapies. 1, 2 Although transcatheter mitral valve implantation (TMVI) is occasionally used in the setting of clinical research for the treatment of native valve disease, in clinical practice it is used to treat patients with bioprosthesis 3, 4 or annuloplasty ring failure 5 or degenerative mitral valve disease with severe mitral annulus calcification (MAC). 6 Nowadays, there are very limited data on commercial TMVI results and the existing evidence is mostly derived from multicentre case series compiling the very first experience of centres with limited follow-up. [7] [8] [9] The lack of standardized recommendations for TMVI and clinical practices has resulted in a wide variability in the indications, techniques, and approaches used. 3, 5, 7, 8 This heterogeneity of data might have limited the reliability of the reported conclusions. 7, 8 We aimed to evaluate the safety and long-term clinical and haemodynamic results of valve-in-valve (ViV), valve-in-ring (ViR), and valvein-MAC (ViMAC) TMVI performed by experienced operators in a single-centre study using the transseptal approach as the default.
Methods

Patient population
All 91 patients undergoing TMVI in our centre from July 2010 to July 2017 were included. Indications for TMVI were severe symptomatic mitral valve disease due to bioprosthesis or ring failure or severe MAC in high-risk or inoperable patients in whom the heart team favoured percutaneous intervention over surgery. A small subset of the population consisted of young women with a desire for pregnancy or current pregnancy in whom TMVI was considered to avoid or delay a surgical reintervention, which should have been bioprosthesis implantation in these specific cases. Data were prospectively collected in local electronic case report forms. Mitral annulus calcification was defined as the presence of severe calcification of the mitral annulus covering at least 180 of the circumference.
Outcomes were defined according to the Mitral Valve Academic Research Consortium (MVARC). 10 Events occurring before the publication of the MVARC were retrospectively defined. Left ventricular outflow tract (LVOT) obstruction was defined as an increase in the LVOT gradient of >30 mmHg in basal conditions as evaluated by echocardiography. Haemodynamically significant LVOT obstruction was defined as a LVOT with a maximum gradient > _50 mmHg in basal conditions. No provocative manoeuvers were systematically performed to detect subclinical LVOT obstruction, and exercise echocardiography was used only if discrepancy between symptoms and LVOT gradient was observed. Valve thrombosis was defined as the presence of at least one thickened leaflet with restricted motion or a mobile mass suggestive of thrombus confirmed by transoesophageal echocardiography (TOE) and contrast computed tomography (CT). Severe structural valve deterioration was defined as an irreversible failure of the transcatheter heart valve (THV) resulting in an increase of the transmitral gradients with a mean gradient >10 mmHg or >5 mmHg change from baseline, or severe, new or worsening (>2þ/4þ) intra-prosthetic mitral regurgitation. 11 All patients signed consent forms before the procedures. The study complies with the Declaration of Helsinki and was carried out in accordance with the local legislation.
Transcatheter mitral valve implantation work-up, approach selection, and procedures
Transcatheter mitral valve implantation work-up description has been previously reported. 12 Briefly, in addition to standard pre-operative examination, TOE and contrast CT were performed in order to identify concomitant diseases contraindicating the procedure (i.e. active endocarditis, severe paravalvular leaks, or partial disinsertion of mitral bioprosthesis or ring), confirm the feasibility of the procedure, evaluate the risk of LVOT obstruction, high residual transmitral gradients and paravalvular leaks, and to determine the size of the THV. The risk of LVOT obstruction was assessed after careful evaluation of all contributing factors [LVOT and left ventricular cavity dimensions, mitral-aorta angle (23) and the morphology of the anterior leaflet and subvalvular apparatus] by TOE and CT and the analysis of the dimensions of the neo-LVOT after simulation of the THV on CT images. 12 In patients with an end-systole neo-LVOT <100 mm 2 , the risk of LVOT obstruction was considered prohibitive.
All procedures were performed by a team of interventional cardiologists and cardiac surgeons, under general anaesthesia, with TOE and fluoroscopy guidance, using the SAPIEN XT or SAPIEN 3 THV (Edwards Lifesciences, Irvine, CA, USA). The default approach was transseptal except for the first two cases, which were performed via the transapical approach. Transseptal and transapical procedures were performed as previously described. 12, 13 Cases with severe MAC judged at high risk for LVOT obstruction underwent a preventive treatment: (i) alcohol septal ablation (ASA) in patients with a high risk or a contraindication for surgery and a risk of LVOT mainly due to the presence of a septal bulge and favourable coronary anatomy for ASA (presence of approachable septal perforator branches) 13 ; (ii) hybrid TMVI using the transatrial approach in patients at high risk but operable and unfavourable anatomy for ASA, in order to resect the anterior leaflet and subvalvular apparatus before the implantation of the THV, and in those with concomitant valvular heart disease requiring surgery. The transatrial hybrid procedures were performed on-pump in the operating room.
14 After sternotomy, the mitral valve was reached through the left atrium. After excision of the anterior leaflet and subvalvular apparatus, a stiff wire (Safari wire, Boston Scientific, Natick, MA, USA) was placed at the apex of the left ventricle. The THV was then advanced very carefully on the wire and deployed on direct visual guidance with a very slow inflation in order to adjust the position if necessary before the final implantation. The Certitude Delivery system was used. Once the THV was implanted and the patient weaned from cardiopulmonary bypass, a TOE evaluation was performed. No contrast injection was used during the procedures. The decision of postdilation or implantation of a second prosthesis relied on the mechanism of the paravalvular leak deducted by careful evaluation (incomplete expansion or malposition).
Antithrombotic therapy
Anticoagulation with intravenous heparin was administered during the procedures (70 UI/Kg for transseptal and transapical TMVI and 300 UI/Kg for transatrial hybrid TMVI). Anticoagulation at therapeutic levels with heparin was restarted 2 h after transseptal and 6 h after transapical and hybrid procedures in the absence of complication. In addition, patients received 75 mg/day of aspirin which was initiated before the procedure.
In the absence of contraindication, patients were discharged with vitamin K antagonists (VKA) with a target international normalized ratio of 2-3 and aspirin 75 mg/day for the first 3 months at least. VKA were discontinued thereafter if TOE confirmed the absence of valve thrombosis in patients who had no other indication for long-term anticoagulation therapy. In patients in whom valve thrombosis was detected, VKA were restarted lifelong. 
Results
Patients
Baseline clinical and echocardiographic characteristics of the study population are displayed in Table 1 . The median age was 73 (57-81) years and 64 patients (70.3%) were women. Five patients (5.5%) with cardiogenic shock underwent a rescue TMVI in an emergent setting.
Patients were judged at high risk for surgery with a median EuroSCORE II of 9.6% (4.0-14.6) and median Logistic EuroSCORE of 16.7% (9.1-31.7). Overall, indications for TMVI were bioprosthesis failure in 34 (37. 3%) patients, ring annuloplasty failure in 30 (33.0%) patients and mitral disease with severe MAC in 27 (29.7%). The median time from last surgery to TMVI was 8 (4-11) years. The initial mitral disease is shown in Supplementary material online, Table S1 . A mean transmitral gradient >5 mmHg was observed in 82.4% of patients and a mitral regurgitation > _2/4 in 52.7%. Seven (25.9%) patients with MAC were considered at high risk for LVOT obstruction, requiring either preventive ASA [2 patients (7.4%), 21 and 97 days before TMVI] or resection of the anterior mitral leaflet using a hybrid approach (five patients, 18.5%). Main clinical and echocardiographic characteristics according to the indication of TMVI (ViV, ViR, and ViMAC) are shown in Table 1 .
Procedural findings and outcomes
The transseptal approach was used in 92.3% of all patients and the SAPIEN 3 THV in the 58.2% of cases. Main procedural findings and outcomes in the study population and according to study groups are shown in Table 2 . Post-dilation was more frequently used in ViR patients (35.7%, P = 0.009 for comparisons between groups) and a second prosthesis was more frequently implanted in ViMAC patients (25.9%, P = 0.025 for comparisons between groups). One patient with emergent rescue TMVI after surgical mitral valve replacement failure died during the procedure due to a hypovolemic shock occurring after multiple manoeuvers to place the THV within the surgical bioprosthesis, which had an intra-atrial, oblique position. These manoeuvers induced a plication of the catheter in the inferior vena cava, which probably ruptured. Overall, technical success was achieved in 84.6% of patients (94.1% of ViV, 80% of ViR, and 77.7% of ViMAC patients, P = 0.196). Two patients (2.2%) required emergent conversion to cardiac surgery: the first patient, with a left atrium of 1.5 L, had a perforation of the ascending aorta during the transseptal catheterization; the second one, with a totally radiolucent annuloplasty ring, had an embolization of the prosthesis in the left atrium despite TOE guidance. A post-TMVI haemodynamically significant LVOT obstruction with a maximum gradient > _50 mmHg was observed in three patients (one ViV and two ViMAC). Two of them were without clinical consequences and the third one underwent successful bailout ASA due to initial haemodynamic compromise. None of the patients with preventive ASA (two patients) or resection of the anterior mitral leaflet had any significant LVOT obstruction. Prosthesis embolization occurred in two patients (2.2%), the aforementioned ViR patient and one ViV patient, due to undersizing of the THV.
Thirty-day outcomes
Thirty-day outcomes according to study groups are displayed in Table 3 . Seven patients [7. 7%; 95% confidence interval (CI) 3.7-15.5] had died, 5.8 (95% CI 2.5-13.4) % of patients with a non-emergent or salvage procedure. Thirty-day mortality among the 5 patients requiring an emergent procedure was 40 (95% CI 11.8-87.4) %. Two patients, both in the ViR group, required delayed surgical mitral valve replacement: one patient, with anterior leaflet repair with patch augmentation who had significant LVOT obstruction and high residual transmitral gradients after TMVI, and the second one, due to a partial disinsertion of the mitral ring with mitral regurgitation. A major stroke occurred in two patients (2.2, 95% CI 0.6-8.6%). An LVOT obstruction with a gradient >30 mmHg was observed in eight (8.9%; 95% CI 4.5-16.9) patients (5.9% in the ViV, 13.3% in the ViR and 7.4% in the ViMAC group, P = 0.649). In one patient this was confirmed after exercise echocardiography. No 30-day valve embolization occurred, although a slight late backwards displacement was observed in three (3.4%) patients with a ViMAC. Asymptomatic partial thrombosis of the prosthesis was detected in eight patients (9.1, 95 CI 4.7-17.4%), one of them being on extracorporeal membrane oxygenation due to advanced cardiac disease. Among them, a mild increase in transmitral gradients was detected in four (50%) patients: two ViR, one ViMAC and one VinV (delta mean gradient: 2.5 ± 1. percutaneous closure of the residual septal defect. In one patient the procedure was performed immediately after TMVI because of a severe right-to-left interatrial shunt resulting in oxygen desaturation after the retrieval of the delivery system. In the other two patients, the procedure was performed 5 and 7 days after TMVI due to the occurrence of heart failure and oxygen desaturation attributable to severe right-to-left interatrial shunt.
Long-term cumulative outcomes
At a median (interquartile range) follow-up of 13 (4-26) months, 30 (33.0%) patients had died, 26.4% from cardiovascular causes. Cumulative rates of all-cause mortality at 1-year and 2-year follow-up were 21.0% (95% CI 9.9-38.8) and 35.7% (95% CI 19.2-56.5), respectively. One-year cardiovascular mortality was 17.3% (95% CI 7.3-34.7) and 2-year, 26.4% (95% CI 12.5-47.1). Table 4 shows cumulative outcomes according to the indication of the procedure. Patients with ViMAC had higher mortality [hazard ration (HR) 2.39, 95% CI 1.01-5.86; P = 0.046] and a trend towards higher cardiovascular mortality (HR 2.80, 95% CI 0.94-8.46; P = 0.162) ( Figure 1A and B) . Univariate predictors of all-cause mortality are shown in Supplementary material online, Table S2 . A ViMAC procedure (HR 3.49, 95% CI 1.44-8.48; P = 0.006), the presence of tricuspid regurgitation >2 (HR 2.73, 95% CI 1.23-1.07; P = 0.014) at baseline and the EuroSCORE-2 (HR 1.04, 95% CI 1.01-1.07; P = 0.009) were independent predictors of allcause cumulative mortality after TMVI. Among ViMAC patients, 12 have died at last follow-up: eight (66.7%) from cardiovascular causes (three procedural related death, two due to heart failure, one sudden death, and two endocarditis) and four (33.3%) from non-cardiac causes.
After hospital discharge, three more ViR patients required surgical mitral valve replacement (P = 0.002, Figure 2A ). Kaplan-Meier curves for surgical mitral valve replacement or death at 2-year follow-up, according to the indication of the procedure, are shown in Figure 2B . The cumulative rates of 2-year re-intervention, stroke, and endocarditis were 8.8%, (95% CI 2.3-27.6), 4.5%, (95% CI 1. Figure 3 shows the changes in New York Heart Association (NYHA) class over time. At 6-month to 1-year follow-up, 72.4% of patients were in NYHA Class I or II (vs. 17.9% at baseline, P < 0.001) and 69.2% of patients alive had at least 1 degree improvement in NYHA class at 6-month to 1-year follow-up.
Subgroup of young women
Twelve young women (mean age: 28 ± 6 years) underwent TMVI: a ViV TMVI was performed in five (41.7%) patients and a ViR TMVI in seven (58.3%). The desire for pregnancy in the near future (11 patients, 91.7%) or current pregnancy (one patient, 8.3%) was taken into consideration for the indication of TMVI. Three of them (25%) had previously undergone two or more cardiac surgeries. All these patients had severe mitral stenosis with a mean transmitral gradient of 13 ± 6 mmHg and three (25%) patients had in addition severe mitral regurgitation. The mean pulmonary artery systolic pressure (PASP) was of 49 ± 17 mmHg, 25% of patients had a PASP >60 mmHg and five (41.7%) patients had right ventricular dysfunction.
No death, stroke, major vascular complication, or life-threatening bleeding occurred among the 12 young women undergoing TMVI ( Table 5) . Two out of the 12 young women had an uneventful pregnancy and delivery after successful TMVI.
Changes in haemodynamics
The mean transmitral gradient decreased from 9.3 ± 3.9 mmHg at baseline to 6.0 ± 2.3 mmHg at discharge (P < 0.001) without changes at 6-month to 1-year follow-up (6.3 ± 2.2 mmHg, P = 0.999). Changes in mean transmitral gradients according to study groups are shown in Figure 4A . The mean mitral valve area increased from 1.07 ± 0.32 cm 2 at baseline to 1.68 ± 0.40 cm 2 (P = 0.013) at discharge and 1.90 ± 0.49 cm 2 at 6-month to 1-year follow-up (P = 0.001 for baseline to 1-year follow-up and P = 0.718 for discharge vs. 6-month to 1-year followup) ( Figure 4B) . Changes in the severity of mitral regurgitation over time are shown in Figure 5A . The mitral regurgitation grade was mild or less in 96.4% of patients at discharge and 90.7% of patients at the 6-month to 1-year follow-up. Moderate or severe mitral regurgitation at discharge was more frequent in patients with ViR procedures (10.7 vs. 0% in the other groups, P = 0.055). At 6-month to 1-year follow-up, 20% of ViR and 8.3% of ViMAC patients had moderate or severe mitral regurgitation, while no case was observed in the ViV group (P = 0.068) ( Figure 5B) .
The severity of tricuspid regurgitation decreased at 6-month to 1-year follow-up (P = 0.009) ( Figure 6 ). Tricuspid regurgitation >2 was observed in 34.2% at discharge and 22.2% at 6-month to 1-year follow-up (vs. 33% at baseline) (P = 0.380). A significant reduction was observed in PASP at 6-month to 1-year follow-up compared with baseline (54 ± 12 to 46 ± 11 mmHg, P = 0.002).
A significant reduction was observed in left ventricular (LV) enddiastolic diameter (51 ± 9 vs. 47 ± 8 mm, P= 0.001) at the 6 to 12 months follow-up. However, no significant changes were observed in LV end-systolic diameter (32 ± 9 vs. 32 ± 9 P = 0.612) and left ventricular ejection fraction over time (58 ± 10 vs. 57± 11, P = 0.561).
Twelve patients had more than 3 years of follow-up and two patients had more than 4 years follow-up. No case of structural valve deterioration was observed.
Discussion
This study shows that TMVI is feasible, appears to be safe when performed by experienced operators and to result in acceptable longterm clinical and haemodynamic outcomes. The anticipated safety concerns and technical challenges have slowed down the expansion of TMVI compared with TAVI. Two major issues have challenged the development of TMVI therapies: the anchoring of prostheses, hindered by the huge differences in systolic pressures between the left ventricle and the left atrium, and the risk of LVOT obstruction, which results from the anatomical proximity between the anterior leaflet and subvalvular apparatus of the mitral valve and the interventricular septum. 15 Surgical bioprostheses or rings and severe MAC provide support for the anchoring of THV with sufficient radial force to counterbalance migration forces. Therefore, this study shows the results of TMVI in the three patient subsets in whom commercial balloon-expandable THVs are currently used.
Although the transapical approach has been associated with an increased risk of mortality in patients undergoing TAVI, its use has been initially favoured over the transvenous, transseptal approach, due to the technical challenges of the transseptal catheterization and navigation in the left atrium using stiff catheters. 3, 7, 8 This study shows that the transseptal approach may be safely used in most patients. Transcatheter mitral valve implantation was associated with a high rate of technical success and resulted in a reduction in transmitral gradients and mitral regurgitation, which were stable over time, and was associated with a low rate of paravalvular leaks. This translated into a significant improvement in functional class. Nonetheless, patients undergoing ViR TMVI had more frequently suboptimal haemodynamic results requiring surgery (compared with ViV and ViMAC), 16 in accordance with previous reports. 8, 17, 18 The type of surgical ring, the technique used for the repair of the anterior leaflet and subvalvular apparatus in addition to other anatomical characteristics may have an impact on the results of TMVI. 12 Of note, a preceding TMVI did not preclude reoperation when necessary. The mortality associated with TMVI in this study was acceptable. Indeed, 30-day mortality is comparable to that of TAVI in real-world patients at high surgical risk [19] [20] [21] including patients with failing aortic bioprostheses, 22 and it is lower than that of reoperation after mitral surgery in current surgical series (12%), confirming the safety of TMVI when performed by experienced teams in accurately selected patients. Previous studies have shown the safety of TMVI when performed in patients with failing bioprostheses (ViV). 3, 8, 26 However, higher mortality rates have been reported for ViR procedures (>8-11 vs. 6.7% in this study) 8, 26 and even more for ViMAC (30 vs. 11%), 7 suggesting a gradient in complexity across these patient subsets and increased experience requirements. In fact, the volume per operator has been identified as a predictor of outcomes in TAVI. 27 Although the initial primary mitral valve disease may have an impact on longterm outcomes after TMVI, no major impact is expected on 30-day outcomes given that parameters assessing the severity of the heart disease before TMVI were similar in all groups. Left ventricular outflow tract obstruction is one of the most feared complications and one of the main limitations of TMVI. However, its risk may be greatly reduced by an accurate screening, selection of patients and planning of the procedure. 12 Only three patients had haemodynamically significant LVOT obstruction in this study, and all of them underwent TMVI at the beginning of our experience. The main mechanism of LVOT obstruction is the displacement of the anterior leaflet and subvalvular apparatus towards the septum, 28 which happens in ViR and ViMAC TMVI. Thus, ASA at a distance from TMVI, as the first option, or hybrid procedures allowing for the resection of the anterior leaflet in patients with a severe MAC in whom ASA is not possible or may not be sufficient to reduce the risk of LVOT obstruction, if there is no contraindication to surgery in addition to the presence of MAC, seem promising strategies. Importantly, no patient having undergone a hybrid procedure or ASA had any significant LVOT obstruction. If it occurs during the procedure, rescue ASA may be lifesaving when haemodynamics is severely compromised. However, when the LVOT obstruction is initially well tolerated, the evolution seems favourable. Indeed, one of the patients with severe LVOT obstruction did not require any intervention early after the procedure and remained asymptomatic during the followup period. Repositionable and retrievable THVs may have an interest in this setting. Finally, a recent paper suggested that intentional percutaneous laceration of the anterior leaflet could prevent the occurrence of severe LVOT obstruction in five patients considered at high risk. 29 However, the anterior leaflet, although lacerated, is not removed and a risk of LVOT obstruction persists. In fact, a gradient was observed in most patients. The efficacy of this technique needs to be confirmed in larger studies. Although overall cumulative long-term mortality in this study was comparable to that of TAVI or percutaneous mitral valve repair in high-risk patients, those with severe MAC had higher late mortality, mainly from cardiovascular causes, despite similar procedural mortality. Reasons for this excess mortality are largely unknown and probably related to patient intrinsic risk profile. Indeed, the presence of MAC is considered as an indicator of atherosclerosis burden, 16 and has been associated with an increased risk of late cardiovascular and overall mortality. 16, 30, 31 An accurate identification of the predictors of late mortality is necessary to improve patient selection and avoid futility and should be of utmost priority for future investigations. Concerns remain, in particular the risk of valve thrombosis, which occurred more frequently early after the procedure, although cases of late thrombosis were detected during the follow-up period. Of note, no symptom was associated with the occurrence of valve thrombosis. Extended anticoagulation therapy seems reasonable in these patients. As for surgical bioprostheses, at least 6 months of VKA therapy may be necessary after TMVI. 1 Although no late THV migration occurred, late slight backward displacements were observed in three ViMAC patients. Even though the risk is reduced by an optimal sizing, this complication may occur even in patients with apparently accurate selection of the THV diameter. Thus, the potential occurrence of THV thrombosis and late backward displacement justifies a close follow-up, with clinical and echocardiographic evaluations, also required to detect valve endocarditis and degeneration. The role of CT in the long-term follow-up of these patients remains to be determined. This study provides new insights to the current evidence on TMVI results. [7] [8] [9] Firstly, this is the study with the longest follow-up period (mean follow-up of 1 year). Secondly, this study provides data on late outcomes including rates of cardiovascular mortality, surgical mitral valve replacement, re-intervention, and endocarditis, for the first time. In particular, late outcomes in patients with ViMAC are unknown. Thirdly, changes in valve haemodynamics (including mitral regurgitation, mean transmitral gradient, and area) and main echocardiographic parameters (PASP, tricuspid regurgitation) are reported for the three subgroups over time, from baseline to the 6-month to 1-year follow-up. Also, this study provides data on changes in functional outcomes over time. Finally, it shows the results of TMVI in Clinical and haemodynamic outcomes of TMVI two subgroups of patients for whom it may be of particular interest: young women desiring pregnancy, given the risks associated with anticoagulation therapy and mechanical prostheses during pregnancy, and patients in cardiogenic shock, who were not evaluated in previous studies.
Limitations
Albeit this is the largest case series from an experienced centre, this is a single-centre study. This however provides optimal homogeneity in patient care and in data collection and analysis, but the results may not be generalizable. The evaluation of functional outcomes was limited to the assessment of the NYHA class. A lack of power to detect differences between groups cannot be ruled out. Although this study included the largest number of patients undergoing TMVI using the transseptal approach, no accurate conclusions can be drawn regarding the impact of the learning curve due to a low event rate, a limited number of patients per group and a different distribution of the study groups (ViMAC procedures were more frequently performed in the second half of the learning curve). There was no central adjudication committee. No provocative manoeuvers were used for the detection of subclinical LVOT obstruction.
Conclusion
In conclusion, when performed by experienced teams in adequately selected high-risk patients, TMVI is feasible, effective and safe and is associated with satisfactory long-term results. Future studies including larger populations and longer follow-up are needed to establish the precise role of TMVI in clinical practice.
